TerminatedNCT00094120
MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
PHASE2 · 60 planned enrolment
- Countries listed
- 1
- Registry update
- January 9, 2008
Registry Intervention View
MSI-1256F (Squalamine Lactate)
Trial registrations containing the exact intervention label MSI-1256F (Squalamine Lactate).
Exact registry label · Not reported
3 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
0 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
TerminatedNCT00089830
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
PHASE2 · 120 planned enrolment
- Countries listed
- 1
- Registry update
- November 28, 2007
TerminatedNCT00333476
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
PHASE2 · 140 planned enrolment
- Countries listed
- 1
- Registry update
- November 28, 2007